Medtronic puts faith in Chinese market
This article was originally published in Clinica
Medtronic has been given permission by the Chinese authorities to set up a wholly foreign owned enterprise and will establish a new manufacturing plant and offices in Shanghai's Zhangjiang Hi-Tech Park. Construction of the production facility is scheduled to start this summer, with assembly of cardiac pacemakers expected to be under way in mid-1997. The first product will be Medtronic's Champion pacing system.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.